Different Infectivity of HIV-1 Strains Is Linked to Number of Envelope Trimers Required for Entry

PLoS Pathogens

Volumn 11, Issue 1, 2015, Pages 1-15

  Brandenberg, Oliver F ^a   Magnus, Carsten ^a   Rusert, Peter ^a   Regoes, Roland R ^b   Trkola, Alexandra ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; GLYCOPROTEIN GP 160; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; GLYCOSYLATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MATHEMATICAL MODEL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN STRUCTURE; STOICHIOMETRY; VIRUS ENTRY; VIRUS INFECTIVITY; VIRUS TRANSMISSION; CELL CULTURE; HEK293 CELL LINE; KINETICS; METABOLISM; PATHOGENICITY; PHYSIOLOGY; PROTEIN MULTIMERIZATION; THEORETICAL MODEL;

HUMAN IMMUNODEFICIENCY VIRUS 1;

CELLS, CULTURED; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HEK293 CELLS; HIV-1; HUMANS; KINETICS; MODELS, THEORETICAL; PROTEIN MULTIMERIZATION; VIRUS INTERNALIZATION;

EID: 84923851915     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004595     Document Type: Article

References (85)

1. Klasse PJ, (2012) The molecular basis of HIV entry. Cell Microbiol 14: 1183–1192.
2. Wilen CB, Tilton JC, Doms RW, (2012) Molecular mechanisms of HIV entry. Adv Exp Med Biol 726: 223–242.
3. Mascola JR, Haynes BF, (2013) HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev 254: 225–244.
4. Klein F, Mouquet H, Dosenovic P, Scheid JF, Scharf L, et al. (2013) Antibodies in HIV-1 vaccine development and therapy. Science 341: 1199–1204.
5. Pancera M, Zhou T, Druz A, Georgiev IS, Soto C, et al. (2014) Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature. 2014 514(7523): 455–61.
6. Pollakis G, Paxton WA, (2012) Use of (alternative) coreceptors for HIV entry. Curr Opin HIV AIDS 7: 440–449.
7. Blumenthal R, Durell S, Viard M, (2012) HIV entry and envelope glycoprotein-mediated fusion. J Biol Chem 287: 40841–40849.
8. Harrison SC, (2008) Viral membrane fusion. Nat Struct Mol Biol 15: 690–698.
9. Cohen FS, Melikyan GB, (2004) The energetics of membrane fusion from binding, through hemifusion, pore formation, and pore enlargement. J Membr Biol 199: 1–14.
10. Melikyan GB, (2008) Common principles and intermediates of viral protein-mediated fusion: the HIV-1 paradigm. Retrovirology 5: 111.
11. Jahn R, Lang T, Sudhof TC, (2003) Membrane fusion. Cell 112: 519–533.
12. Gallo SA, Reeves JD, Garg H, Foley B, Doms RW, et al. (2006) Kinetic studies of HIV-1 and HIV-2 envelope glycoprotein-mediated fusion. Retrovirology 3: 90.
13. Yang X, Kurteva S, Ren X, Lee S, Sodroski J, (2005) Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1. J Virol 79: 12132–12147.
14. Klasse PJ, (2007) Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody. Virology 369: 245–262.
15. Magnus C, Rusert P, Bonhoeffer S, Trkola A, Regoes RR, (2009) Estimating the stoichiometry of human immunodeficiency virus entry. J Virol 83: 1523–1531.
16. Floyd DL, Ragains JR, Skehel JJ, Harrison SC, van Oijen AM, (2008) Single-particle kinetics of influenza virus membrane fusion. Proc Natl Acad Sci U S A 105: 15382–15387.
17. Ivanovic T, Choi JL, Whelan SP, van Oijen AM, Harrison SC, (2013) Influenza-virus membrane fusion by cooperative fold-back of stochastically induced hemagglutinin intermediates. Elife 2: e00333.
18. Danieli T, Pelletier SL, Henis YI, White JM, (1996) Membrane fusion mediated by the influenza virus hemagglutinin requires the concerted action of at least three hemagglutinin trimers. J Cell Biol 133: 559–569.
19. Sougrat R, Bartesaghi A, Lifson JD, Bennett AE, Bess JW, et al. (2007) Electron tomography of the contact between T cells and SIV/HIV-1: implications for viral entry. PLoS Pathog 3: e63.
20. Kuhmann SE, Platt EJ, Kozak SL, Kabat D, (2000) Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1. J Virol 74: 7005–7015.
21. Platt EJ, Durnin JP, Shinde U, Kabat D, (2007) An allosteric rheostat in HIV-1 gp120 reduces CCR5 stoichiometry required for membrane fusion and overcomes diverse entry limitations. J Mol Biol 374: 64–79.
22. Burton DR, Poignard P, Stanfield RL, Wilson IA, (2012) Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 337: 183–186.
23. Chertova E, Bess Jr JW, JrCrise BJ, Sowder IR, Schaden TM, et al. (2002) Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol 76: 5315–5325.
24. Layne SP, Merges MJ, Dembo M, Spouge JL, Conley SR, et al. (1992) Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. Virology 189: 695–714.
25. Zhu P, Chertova E, Bess J, JrLifson JD, Arthur LO, et al. (2003) Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions. Proc Natl Acad Sci U S A 100: 15812–15817.
26. Zhu P, Liu J, Bess J, JrChertova E, Lifson JD, et al. (2006) Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441: 847–852.
27. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S, (2008) Molecular architecture of native HIV-1 gp120 trimers. Nature 455: 109–113.
28. Chojnacki J, Staudt T, Glass B, Bingen P, Engelhardt J, et al. (2012) Maturation-dependent HIV-1 surface protein redistribution revealed by fluorescence nanoscopy. Science 338: 524–528.
29. Louder MK, Sambor A, Chertova E, Hunte T, Barrett S, et al. (2005) HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity. Virology 339: 226–238.
30. Freed EO, Myers DJ, Risser R, (1989) Mutational analysis of the cleavage sequence of the human immunodeficiency virus type 1 envelope glycoprotein precursor gp160. J Virol 63: 4670–4675.
31. Guo HG, Veronese FM, Tschachler E, Pal R, Kalyanaraman VS, et al. (1990) Characterization of an HIV-1 point mutant blocked in envelope glycoprotein cleavage. Virology 174: 217–224.
32. Freed EO, Delwart EL, Buchschacher GL, JrPanganiban AT, (1992) A mutation in the human immunodeficiency virus type 1 transmembrane glycoprotein gp41 dominantly interferes with fusion and infectivity. Proc Natl Acad Sci U S A 89: 70–74.
33. Carlson LA, Briggs JA, Glass B, Riches JD, Simon MN, et al. (2008) Three-dimensional analysis of budding sites and released virus suggests a revised model for HIV-1 morphogenesis. Cell Host Microbe 4: 592–599.
34. Cao J, Sullivan N, Desjardin E, Parolin C, Robinson J, et al. (1997) Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. J Virol 71: 9808–9812.
35. Wyatt R, Sullivan N, Thali M, Repke H, Ho D, et al. (1993) Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. J Virol 67: 4557–4565.
36. Stamatatos L, Wiskerchen M, Cheng-Mayer C, (1998) Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication. AIDS Res Hum Retroviruses 14: 1129–1139.
37. Palmer C, Balfe P, Fox D, May JC, Frederiksson R, et al. (1996) Functional characterization of the V1V2 region of human immunodeficiency virus type 1. Virology. United States pp 436–449.
38. Brandenberg OF, Rusert P, Magnus C, Weber J, Boni J, et al. (2014) Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain's exceptional capacity for sequence variation. Retrovirology 11: 75.
39. Egan MA, Carruth LM, Rowell JF, Yu X, Siliciano RF, (1996) Human immunodeficiency virus type 1 envelope protein endocytosis mediated by a highly conserved intrinsic internalization signal in the cytoplasmic domain of gp41 is suppressed in the presence of the Pr55gag precursor protein. J Virol 70: 6547–6556.
40. Yuste E, Reeves JD, Doms RW, Desrosiers RC, (2004) Modulation of Env content in virions of simian immunodeficiency virus: correlation with cell surface expression and virion infectivity. J Virol 78: 6775–6785.
41. Platt EJ, Durnin JP, Kabat D, (2005) Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus. J Virol 79: 4347–4356.
42. Platt EJ, Kozak SL, Durnin JP, Hope TJ, Kabat D, (2010) Rapid dissociation of HIV-1 from cultured cells severely limits infectivity assays, causes the inactivation ascribed to entry inhibitors, and masks the inherently high level of infectivity of virions. J Virol 84: 3106–3110.
43. Moore PL, Ranchobe N, Lambson BE, Gray ES, Cave E, et al. (2009) Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog 5: e1000598.
44. Rao M, Peachman KK, Kim J, Gao G, Alving CR, et al. (2013) HIV-1 Variable Loop 2 and its Importance in HIV-1 Infection and Vaccine Development. Curr HIV Res 11: 427–438.
45. Los Alamos HIV database: HIV-1/SIVcpz curated alignment 2013.
46. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285–289.
47. Wibmer CK, Bhiman JN, Gray ES, Tumba N, Abdool Karim SS, et al. (2013) Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog 9: e1003738.
48. Wu X, Changela A, O'Dell S, Schmidt SD, Pancera M, et al. (2011) Immunotypes of a Quaternary Site of HIV-1 Vulnerability and Their Recognition by Antibodies. J Virol 85: 4578–4585.
49. Lu J, Deeks SG, Hoh R, Beatty G, Kuritzkes BA, et al. (2006) Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J Acquir Immune Defic Syndr 43: 60–64.
50. Reeves JD, Lee FH, Miamidian JL, Jabara CB, Juntilla MM, et al. (2005) Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J Virol 79: 4991–4999.
51. Eckert DM, Kim PS, (2001) Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 70: 777–810.
52. Risselada HJ, Grubmuller H, (2012) How SNARE molecules mediate membrane fusion: recent insights from molecular simulations. Curr Opin Struct Biol 22: 187–196.
53. Chernomordik LV, Kozlov MM, (2008) Mechanics of membrane fusion. Nat Struct Mol Biol 15: 675–683.
54. Liu W, Parpura V, (2010) SNAREs: could they be the answer to an energy landscape riddle in exocytosis? ScientificWorldJournal 10: 1258–1268.
55. Grafmuller A, Shillcock J, Lipowsky R, (2009) The fusion of membranes and vesicles: pathway and energy barriers from dissipative particle dynamics. Biophys J 96: 2658–2675.
56. Magnus C, Regoes RR, (2011) Restricted occupancy models for neutralization of HIV virions and populations. J Theor Biol 283: 192–202.
57. Haim H, Strack B, Kassa A, Madani N, Wang L, et al. (2011) Contribution of Intrinsic Reactivity of the HIV-1 Envelope Glycoproteins to CD4-Independent Infection and Global Inhibitor Sensitivity. PLoS Pathog 7: e1002101.
58. Munro JB, Gorman J, Ma X, Zhou Z, Arthos J, et al. (2014) Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions. Science.
59. White TA, Bartesaghi A, Borgnia MJ, Meyerson JR, de la Cruz MJ, et al. (2010) Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure. PLoS Pathog 6: e1001249.
60. Ho SH, Tasca S, Shek L, Li A, Gettie A, et al. (2007) Coreceptor switch in R5-tropic simian/human immunodeficiency virus-infected macaques. J Virol 81: 8621–8633.
61. Mohrmann R, de Wit H, Verhage M, Neher E, Sorensen JB, (2010) Fast vesicle fusion in living cells requires at least three SNARE complexes. Science 330: 502–505.
62. Shi L, Shen QT, Kiel A, Wang J, Wang HW, et al. (2012) SNARE proteins: one to fuse and three to keep the nascent fusion pore open. Science 335: 1355–1359.
63. Magnus C, Brandenberg OF, Rusert P, Trkola A, Regoes RR, (2013) Mathematical models: A key to understanding HIV envelope interactions? J Immunol Methods 398–399: 1–18.
64. Bourinbaiar AS, (1994) The ratio of defective HIV-1 particles to replication-competent infectious virions. Acta Virol 38: 59–61.
65. Poignard P, Moulard M, Golez E, Vivona V, Franti M, et al. (2003) Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J Virol 77: 353–365.
66. Salzwedel K, Berger EA, (2000) Cooperative subunit interactions within the oligomeric envelope glycoprotein of HIV-1: functional complementation of specific defects in gp120 and gp41. Proc Natl Acad Sci U S A 97: 12794–12799.
67. Rusert P, Krarup A, Magnus C, Brandenberg OF, Weber J, et al. (2011) Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies. J Exp Med 208: 1419–1433.
68. Magnus C, Regoes RR, (2010) Estimating the Stoichiometry of HIV Neutralization. PLoS Comput Biol 6: e1000713.
69. Fang Q, Lindau M, (2014) How Could SNARE Proteins Open a Fusion Pore? Physiology (Bethesda) 29: 278–285.
70. Markosyan RM, Cohen FS, Melikyan GB, (2003) HIV-1 envelope proteins complete their folding into six-helix bundles immediately after fusion pore formation. Mol Biol Cell 14: 926–938.
71. Li F, Pincet F, Perez E, Eng WS, Melia TJ, et al. (2007) Energetics and dynamics of SNAREpin folding across lipid bilayers. Nat Struct Mol Biol 14: 890–896.
72. Liu W, Montana V, Parpura V, Mohideen U, (2009) Single Molecule Measurements of Interaction Free Energies Between the Proteins Within Binary and Ternary SNARE Complexes. J Nanoneurosci 1: 120–129.
73. Gao Y, Zorman S, Gundersen G, Xi Z, Ma L, et al. (2012) Single reconstituted neuronal SNARE complexes zipper in three distinct stages. Science 337: 1340–1343.
74. Sinha R, Ahmed S, Jahn R, Klingauf J, (2011) Two synaptobrevin molecules are sufficient for vesicle fusion in central nervous system synapses. Proc Natl Acad Sci U S A 108: 14318–14323.
75. Markin VS, Albanesi JP, (2002) Membrane fusion: stalk model revisited. Biophys J 82: 693–712.
76. Kuzmin PI, Zimmerberg J, Chizmadzhev YA, Cohen FS, (2001) A quantitative model for membrane fusion based on low-energy intermediates. Proc Natl Acad Sci U S A 98: 7235–7240.
77. Kozlov MM, Chernomordik LV, (1998) A mechanism of protein-mediated fusion: coupling between refolding of the influenza hemagglutinin and lipid rearrangements. Biophys J 75: 1384–1396.
78. Wiederhold K, Fasshauer D, (2009) Is assembly of the SNARE complex enough to fuel membrane fusion? J Biol Chem 284: 13143–13152.
79. Spear M, Guo J, Wu Y, (2012) The trinity of the cortical actin in the initiation of HIV-1 infection. Retrovirology 9: 45.
80. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, et al. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46: 1896–1905.
81. Moore PL, Ranchobe N, Lambson BE, Gray ES, Cave E, et al. (2009) Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog 5: e1000598.
82. Wild C, Greenwell T, Matthews T, (1993) A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses 9: 1051–1053.
83. Yang X, Kurteva S, Lee S, Sodroski J, (2005) Stoichiometry of antibody neutralization of human immunodeficiency virus type 1. J Virol 79: 3500–3508.
84. Team RC (2013) R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing.
85. Mann AM, Rusert P, Berlinger L, Kuster H, Gunthard HF, et al. (2009) HIV sensitivity to neutralization is determined by target and virus producer cell properties. AIDS 23: 1659–1667.